Cargando…

In situ Metabolomics of Metabolic Reprogramming Involved in a Mouse Model of Type 2 Diabetic Kidney Disease

The in situ metabolic profiling of the kidney is crucial to investigate the complex metabolic reprogramming underlying diabetic kidney disease (DKD) and to allow exploration of potential metabolic targets to improve kidney function. However, as the kidney is a highly heterogeneous organ, traditional...

Descripción completa

Detalles Bibliográficos
Autores principales: Linnan, Bai, Yanzhe, Wang, Ling, Zhang, Yuyuan, Liu, Sijia, Chen, Xinmiao, Xie, Fengqin, Li, Xiaoxia, Wang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670437/
https://www.ncbi.nlm.nih.gov/pubmed/34916961
http://dx.doi.org/10.3389/fphys.2021.779683
_version_ 1784614980077748224
author Linnan, Bai
Yanzhe, Wang
Ling, Zhang
Yuyuan, Liu
Sijia, Chen
Xinmiao, Xie
Fengqin, Li
Xiaoxia, Wang
author_facet Linnan, Bai
Yanzhe, Wang
Ling, Zhang
Yuyuan, Liu
Sijia, Chen
Xinmiao, Xie
Fengqin, Li
Xiaoxia, Wang
author_sort Linnan, Bai
collection PubMed
description The in situ metabolic profiling of the kidney is crucial to investigate the complex metabolic reprogramming underlying diabetic kidney disease (DKD) and to allow exploration of potential metabolic targets to improve kidney function. However, as the kidney is a highly heterogeneous organ, traditional metabolomic methods based on bulk analysis that produce an averaged measurement are inadequate. Herein, we employed an in situ metabolomics approach to discover alternations of DKD-associated metabolites and metabolic pathways. A series of histology-specific metabolic disturbances were discovered in situ using airflow-assisted desorption electrospray ionization mass spectrometry imaging (AFADESI–MSI). In combination with integrated metabolomics analysis, five dysfunctional metabolic pathways were identified and located in the kidneys of type-2 DKD mice simultaneously for the first time, including taurine metabolism, arginine and proline metabolism, histidine metabolism, biosynthesis of unsaturated fatty acids, and fatty acid degradation pathways. As crucial nodes of metabolic pathways, five dysregulated rate-limiting enzymes related to altered metabolic pathways were further identified. These findings reveal alternations from metabolites to enzymes at the molecular level in the progression of DKD and provide insights into DKD-associated metabolic reprogramming.
format Online
Article
Text
id pubmed-8670437
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86704372021-12-15 In situ Metabolomics of Metabolic Reprogramming Involved in a Mouse Model of Type 2 Diabetic Kidney Disease Linnan, Bai Yanzhe, Wang Ling, Zhang Yuyuan, Liu Sijia, Chen Xinmiao, Xie Fengqin, Li Xiaoxia, Wang Front Physiol Physiology The in situ metabolic profiling of the kidney is crucial to investigate the complex metabolic reprogramming underlying diabetic kidney disease (DKD) and to allow exploration of potential metabolic targets to improve kidney function. However, as the kidney is a highly heterogeneous organ, traditional metabolomic methods based on bulk analysis that produce an averaged measurement are inadequate. Herein, we employed an in situ metabolomics approach to discover alternations of DKD-associated metabolites and metabolic pathways. A series of histology-specific metabolic disturbances were discovered in situ using airflow-assisted desorption electrospray ionization mass spectrometry imaging (AFADESI–MSI). In combination with integrated metabolomics analysis, five dysfunctional metabolic pathways were identified and located in the kidneys of type-2 DKD mice simultaneously for the first time, including taurine metabolism, arginine and proline metabolism, histidine metabolism, biosynthesis of unsaturated fatty acids, and fatty acid degradation pathways. As crucial nodes of metabolic pathways, five dysregulated rate-limiting enzymes related to altered metabolic pathways were further identified. These findings reveal alternations from metabolites to enzymes at the molecular level in the progression of DKD and provide insights into DKD-associated metabolic reprogramming. Frontiers Media S.A. 2021-11-30 /pmc/articles/PMC8670437/ /pubmed/34916961 http://dx.doi.org/10.3389/fphys.2021.779683 Text en Copyright © 2021 Linnan, Yanzhe, Ling, Yuyuan, Sijia, Xinmiao, Fengqin and Xiaoxia. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Physiology
Linnan, Bai
Yanzhe, Wang
Ling, Zhang
Yuyuan, Liu
Sijia, Chen
Xinmiao, Xie
Fengqin, Li
Xiaoxia, Wang
In situ Metabolomics of Metabolic Reprogramming Involved in a Mouse Model of Type 2 Diabetic Kidney Disease
title In situ Metabolomics of Metabolic Reprogramming Involved in a Mouse Model of Type 2 Diabetic Kidney Disease
title_full In situ Metabolomics of Metabolic Reprogramming Involved in a Mouse Model of Type 2 Diabetic Kidney Disease
title_fullStr In situ Metabolomics of Metabolic Reprogramming Involved in a Mouse Model of Type 2 Diabetic Kidney Disease
title_full_unstemmed In situ Metabolomics of Metabolic Reprogramming Involved in a Mouse Model of Type 2 Diabetic Kidney Disease
title_short In situ Metabolomics of Metabolic Reprogramming Involved in a Mouse Model of Type 2 Diabetic Kidney Disease
title_sort in situ metabolomics of metabolic reprogramming involved in a mouse model of type 2 diabetic kidney disease
topic Physiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670437/
https://www.ncbi.nlm.nih.gov/pubmed/34916961
http://dx.doi.org/10.3389/fphys.2021.779683
work_keys_str_mv AT linnanbai insitumetabolomicsofmetabolicreprogramminginvolvedinamousemodeloftype2diabetickidneydisease
AT yanzhewang insitumetabolomicsofmetabolicreprogramminginvolvedinamousemodeloftype2diabetickidneydisease
AT lingzhang insitumetabolomicsofmetabolicreprogramminginvolvedinamousemodeloftype2diabetickidneydisease
AT yuyuanliu insitumetabolomicsofmetabolicreprogramminginvolvedinamousemodeloftype2diabetickidneydisease
AT sijiachen insitumetabolomicsofmetabolicreprogramminginvolvedinamousemodeloftype2diabetickidneydisease
AT xinmiaoxie insitumetabolomicsofmetabolicreprogramminginvolvedinamousemodeloftype2diabetickidneydisease
AT fengqinli insitumetabolomicsofmetabolicreprogramminginvolvedinamousemodeloftype2diabetickidneydisease
AT xiaoxiawang insitumetabolomicsofmetabolicreprogramminginvolvedinamousemodeloftype2diabetickidneydisease